Streck Introduces Flow Cytometry Control for CD117
10 May 2013

Streck, Inc., has announced the introduction of CD-Chex™ CD117, the first and only commercially available flow cytometry control for CD117.

CD-Chex 117 eliminates the need for laboratories to hold and validate patient samples to use as a control for CD117, saving time and money.

CD-Chex CD117 is designed to represent abnormal peripheral blood leukocytes similar to a hematolymphoid neoplastic patient sample. The product possesses surface CD117 that is detectable with fluorescent monoclonal antibodies by flow cytometry. The CD117 positive abnormal leukocytes are distinguishable from normal leukocytes on the basis of light scatter properties, a low level of CD45 expression and heterogeneous CD117 expression.

CD-Chex CD117 features 30-day open-vial stability and 90-day closed-vial stability.

Streck also offers CD-Chex™ Plus, a positive procedural control for monitoring immunophenotyping by flow cytometry. It provides the most assayed CD markers in the industry on a single control, including those on the HIV panel of markers and a normal level of CD34+ cells. CD-Chex Plus is manufactured from normal human peripheral blood leukocytes and erythrocytes and is available in two clinically relevant levels of CD4+ cells.

CD-Chex CD 117 is for Research Use Only. Not for use in diagnostic procedures.

Request Info


Company website

Tags: CD117

Streck Laboratories Inc.
profile photo

Sonia Nicholas
Clinical Diagnostics Editor